Table_1_Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials.docx

IntroductionThe aims of this study is to analyze the risk of major adverse cardiovascular events (MACEs) in patients with psoriasis treated with secukinumab and ixekizumab.MethodologyWe systematically identified randomized controlled trials (RCTs) that focused on the treatment of psoriasis with secukinumab and ixekizumab by conducting computerized searches of PubMed, Embase, and the Cochrane Library databases, spanning from their inception to October 31st, 2022. The search terms used included psoriasis, secukinumab, ixekizumab, and randomized controlled trial. Two independent evaluators conducted literature screening, data extraction, and assessed the quality of included studies based on predetermined inclusion and exclusion criteria. The gather data was subjected to meta-analysis using the statistical software RevMan 5.4.ResultsA total of 20 articles, encompassing 23 randomized controlled trials involving 10,746 psoriasis patients were included in the analysis. During the double-blind treatment period, the meta-analysis results indicated the following: There was no significant difference in the incidence of MACEs between the secukinumab and placebo groups [RR = 0.61, 95% CI (0.26, 1.44), p = 0.26]. Similarly, there was no significant difference in the incidence of MACEs with ixekizumab compared to the placebo group [RR = 0.47, 95% CI (0.15, 1.47), p = 0.20]. Furthermore, no significant difference in the incidence of MACEs was observed between secukinumab 300 mg and secukinumab 150 mg treatment groups [RR = 1.00, 95% CI (0.23, 4.35), p = 1.00]. Likewise, there was no significant difference in the incidence of MACEs between the ixekizumab Q4W (every 4 weeks) and ixekizumab Q2W (every 2 weeks) administration groups [RR = 4.01, 95% CI (0.45, 35.89), p = 0.21].ConclusionThe findings of this study suggest that neither secukinumab nor ixekizumab is significantly associated with the risk of MACEs in patients with psoriasis during double-blind treatment.Systematic review registration: Unique Identifier: CRD42022373756 https://www.crd.york.ac.uk/.</p

Coronary calcification was grouped as follows: spotty, length of calcium <3/2 of the vessel diameter and width <2/3 of the vessel diameter (A); medium, length of calcium ≥3/2 of the vessel diameter and width <2/3 of the vessel diameter or length of calcium <3/2 the vessel diameter and width ≥2/3 of the vessel diameter (B); and heavy, length of calcium burden ≥3/2 of the vessel diameter and width ≥2/3 of the vessel diameter (C).

<p>Coronary calcification was grouped as follows: spotty, length of calcium <3/2 of the vessel diameter and width <2/3 of the vessel diameter (A); medium, length of calcium ≥3/2 of the vessel diameter and width <2/3 of the vessel diameter or length of calcium <3/2 the vessel diameter and width ≥2/3 of the vessel diameter (B); and heavy, length of calcium burden ≥3/2 of the vessel diameter and width ≥2/3 of the vessel diameter (C).</p

Logistic regression analysis of the effect of calcification on periprocedural myocardial infarction according to the tertiles of the coronary artery calcium score.

<p>Abbreviations were as followed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0082835#pone-0082835-t002" target="_blank">Table 2</a>.</p

Baseline characteristics among the four groups of subjects.

<p>BMI indicates body mass index; HCHO, hypercholesterolemia; DM, diabetes mellitus; CAD, coronary artery disease; MI, myocardial infarction; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; FBG, fasting blood glucose; CR, serum creatinine; CK, creatine kinase; LVEF, left ventricle ejection fraction; CACS, coronary artery calcium score.</p><p>^b p<0.01 between the two groups.^a indicates a significant difference of p<0.05 between the S and the C group and </p><p>^d p<0.01 between the two groups.^c indicates a significant difference of p<0.05 between the M and the C group and </p><p>^f p<0.01 between the two groups.^e indicates a significant difference of p<0.05 between the H and the C group and </p

Logistic regression analysis of the effect of calcification on periprocedural myocardial infarction according to the morphology of target lesion calcium.

<p>Abbreviations were as followed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0082835#pone-0082835-t002" target="_blank">Table 2</a>.</p

Logistic regression analysis of the effect of calcification on periprocedural myocardial infarction in the four groups.

<p>CI indicates confidence interval. Other abbreviations were as followed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0082835#pone-0082835-t002" target="_blank">Table 2</a>.</p><p>Age and gender were adjusted in logistic regression analysis in Model 1; age, sex, BMI, hypercholesterolemia, diabetes mellitus, hypertension, smoking, and diseased vessels were adjusted in Model 2.</p><p>P^a indicates the significance between the S and the C group in a crude Logistic regression analysis; P^b indicates the significance between the M and the C group in a Logistic regression analysis in model 1;</p><p>P^c indicates the significance between the H and the C group in a Logistic regression analysis in model 2;</p